Stensgaard, S.; Thomsen, A.; Helstrup, S.; Meldgaard, P.; Sorensen, B.S.
Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor. Cancers 2023, 15, 5628.
https://doi.org/10.3390/cancers15235628
AMA Style
Stensgaard S, Thomsen A, Helstrup S, Meldgaard P, Sorensen BS.
Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor. Cancers. 2023; 15(23):5628.
https://doi.org/10.3390/cancers15235628
Chicago/Turabian Style
Stensgaard, Simone, Astrid Thomsen, Sofie Helstrup, Peter Meldgaard, and Boe S. Sorensen.
2023. "Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor" Cancers 15, no. 23: 5628.
https://doi.org/10.3390/cancers15235628
APA Style
Stensgaard, S., Thomsen, A., Helstrup, S., Meldgaard, P., & Sorensen, B. S.
(2023). Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor. Cancers, 15(23), 5628.
https://doi.org/10.3390/cancers15235628